IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY
Open Access
- 1 August 2006
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 34 (8) , 1336-1344
- https://doi.org/10.1124/dmd.106.009258
Abstract
The effects of hepatic uptake and efflux transporters on erythromycin (ERY) disposition and metabolism were examined by comparing results from rat hepatic microsomes, freshly isolated hepatocytes, and in vivo studies. Uptake studies carried out in freshly isolated rat hepatocytes showed that ERY and its metabolite (N-demethyl-ERY) are substrates of Oatp1a4 and Oatp1b2. Whereas rifampin and GG918 [GF120918: N-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamine] exerted minimal effects on metabolism in microsomes, rifampin (2.5 μM) and GG918 (0.5 μM) significantly decreased and increased ERY metabolism in hepatocytes, respectively. Concentration-time course studies further demonstrated that, compared with the intracellular N-demethyl-ERY control area under the curve (AUC) (0.795 ± 0.057 μM · min), a decreased AUC (0.513 ± 0.028 μM · min, p < 0.005) was observed when ERY was coincubated with rifampin, and an increased AUC (2.14 ± 0.21 μM · min, p < 0.05) was found when GG918 was present. The results of the i.v. bolus studies showed that, compared with the ERY clearance of the controls (47.2 ± 12.5 ml/min/kg for the rifampin group and 42.1 ± 5.7 for the GG918 group), a decreased blood clearance, 29.8 ± 6.1 ml/min/kg (p < 0.05) and 21.7 ± 9.0 ml/min/kg (p < 0.01), was observed when rifampin or GG918, respectively, was coadministered. When either inhibitor was codosed with ERY, volume of distribution at steady state was unchanged, but t1/2 and mean residence time significantly increased compared with the controls. Hepatic uptake and efflux transporters modulate intracellular concentrations of ERY, thereby affecting metabolism. The interplay of transporters and enzymes must be considered in evaluating potential drug-drug interactions.Keywords
This publication has 28 references indexed in Scilit:
- Unmasking the dynamic interplay between efflux transporters and metabolic enzymesInternational Journal of Pharmaceutics, 2004
- Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional propertiesPflügers Archiv - European Journal of Physiology, 2004
- CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and MidazolamThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Transporter-Enzyme Interactions: Implications for Predicting Drug-Drug Interactions from In Vitro DataCurrent Drug Metabolism, 2003
- In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion ModelThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4The Journal of Pharmacology and Experimental Therapeutics, 2002
- Automated, fast and sensitive quantification of drugs in blood by liquid chromatography–mass spectrometry with on-line extraction: immunosuppressantsJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Interspecies Correlation of the Pharmacokinetics of Erythromycin, Oleandomycin, and TylosinJournal of Pharmaceutical Sciences, 1985
- Noncompartmental Determination of the Steady‐State Volume of DistributionJournal of Pharmaceutical Sciences, 1979